Table 1 Canonical pathways enriched (P < 0.001) among genes down-regulated or up-regulated in the Gns group versus the Control group
Pathway | Input number | Background number | Corrected P-value | Genes |
|---|---|---|---|---|
Pathways enriched among down-regulated genes | ||||
 Cell cycle | 14 | 124 | 1.10E-07 | PKMYT1, PLK1, CDC25A, TTK, CDC20, CDC25C, CCNA2, CCNB2, |
 Oocyte meiosis | 8 | 110 | 0.003 | BUB1B, CDC45, CCNB1, CDC6, ORC6, ESPL1 PKMYT1, PLK1, CDC20, CDC25C, CCNB2, AURKA, CCNB1, ESPL1 |
 Steroid hormone biosynthesis | 6 | 57 | 0.003 | CYP19A1, HSD11B2, CYP17A1, CYP21A2 |
 Progesterone-mediated oocyte maturation | 7 | 86 | 0.003 | PKMYT1, PLK1, CDC25A, CCNB2, CDC25C, CCNA2, CCNB1 |
 Ovarian steroidogenesis | 5 | 51 | 0.0125 | FSHR, CYP19A1, CYP17A1, LHCGR |
Pathways enriched among up-regulated genes | ||||
 Cytokine–cytokine receptor interaction | 49 | 265 | 2.68E-10 | TNFSF11, CCL28, IL1B, CCR2, CXCL3, OSM, PPBP, TNF, IL10, TNFSF8, CCL4, CXCL8, CXCR4, CD40, IL10RA, IL1R1, FLT3, CCR1, LTA, CCR5, TNFRSF11A, TGFBR2, CCL4L2, TNFRSF18, CCL22, CXCL2, CCL8, TNFSF10, CCL2, CCL20, IL6R, CSF2RA, CCL3L1, TNFSF14, TNFRSF8, TNFSF13B, IL1R2, IL6, CSF2RB, CCL3, CCR6, TNFRSF4, CRLF2, CCL7, IL18R1, IL18RAP, TNFRSF1B, IL18, CSF3R |
 Chemokine signaling pathway | 35 | 189 | 9.0E-08 | CCL28, WAS, CCR2, CXCL3, PRKCB, PPBP, CCL4, HCK, CXCL8, CXCR4, PIK3R5, DOCK2, CCR1, CCR5, ARRB2, CCL4L2, CCL22, CXCL2, CCL8, CCL2, CCL20, CCL3L1, ADCY7, CCR6, VAV1, ADCY4, FGR, CCL3, PIK3CG |
 NF-kappaB signaling pathway | 23 | 91 | 1.4E-07 | CCL7, NCF1, PLCB2, GNGT2,TNFSF13B, PLAU, PRKCB, TNF, BLNK, BTK, CCL4, CXCL8, CD40, LTA, BCL2A1, TNFRSF11A, CCL4L2, CXCL2, ICAM1, CD14, SYK, TNFSF14, IL1B, IL1R1, TNFSF11, LY96, GADD45B |